Notice of Proposed Sale · 144

Vaxcyte, Inc.

PCVXNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Aug 5, 2026Accepted Aug 5, 2026, 4:06 PM EDTFiling CIK 1886794Accession 0001969223-26-000851

View company →Permanent SEC source ↗

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer: Vaxcyte, Inc.
Issuer CIK: 0001649094
SEC file number: 001-39323
Phone: 650-837-0111
Person for whose account securities are to be sold: Dhaliwal Harpreet S.
Relationships to issuer: Officer
Street: 825 INDUSTRIAL ROAD, STE. 300
City: SAN CARLOS
State / country code: CA
Postal code: 94070

Securities proposed for sale

Securities proposed for sale · 1 reported row
Security	Proposed units	Aggregate market value	Units outstanding	Approximate sale date	Exchange	Broker / market maker
Common	17,000	935,000.00	144,397,682	08/05/2026	NASDAQ	UBS Financial Services, Inc.

Broker / market maker — proposed row 1, entry 1

Name: UBS Financial Services, Inc.
Street: 11 Madison Ave
Street (continued): 4th Floor
City: New York
State / country code: NY
Postal code: 10010

Acquisition of securities to be sold

Acquisition of securities to be sold · 1 reported row
Security	Acquired	Nature of acquisition	Acquired from	Amount acquired	Gift transaction	Payment date	Nature of payment
Common	08/05/2026	Exercise of Stock Options	Issuer	17,000	N	08/05/2026	Cash

Prior-sale reporting

Nothing to report for the preceding three months: Y

Notice signature

Notice date: 08/05/2026
Signed: /s/ UBS Financial Services, Inc. as attorney-in-fact for Harpreet Dhaliwal
Plan adoption dates: 04/06/2026

Company context

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent PCV candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of IPD and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, has generated positive Phase 2 clinical results in both adults and infants and is designed to cover more serotypes than any PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise.

Current securities

PCVXNASDAQ · EQUITY · Current

Get the free weekly BCS email.